
International Neoantigen Summit 2025
Date: 24-26 June
Location: Amsterdam, Netherlands
We are delighted to share that Ola Nilsson, Head of Neoantigen Production, Development & Clinical Processing at Neogap Therapeutics, will present pTTL (personalised Tumour-Trained Lymphocytes) at the 8th International Neoantigen Summit 2025. His presentation will focus on Neogap’s ongoing first-in-human trial for stage IV colorectal cancer, highlighting how pTTL uses autologous T cells from regional lymph nodes to target patient-specific neoantigens, offering a novel approach in adoptive T cell therapy.
More information at International Neoantigen Summit.
Previous events

EIC Soft-landing Programme 2025
Date: 9-13 June
Location: Boston, USA
During the EIC Soft-landing Programme for Healthcare and Life Sciences in Boston, Samuel Svensson, CEO of Neogap Therapeutics, will showcase our technology to investors and potential partners and join networking sessions. ”Being selected for the EIC Soft-landing Programme is a strong validation of the relevance of our technology in a global innovation context. This programme offers us a concrete opportunity to strengthen our presence in the US market and build new relationships,” says Samuel Svensson.
More information at Neogap news.

SACCNY Innovate Nordics 2025 – Grand Pitch Finale
Date: 19-21 May
Location: New York, USA
Our COO Andrea Salmén will represent Neogap during the Innovate Nordics 2025 Acceleration Program in New York, hosted by Swedish-American Chamber of Commerce – New York (SACCNY) and EY. Andrea will participate in the Grand Pitch Finale, meet with investors, explore new partnerships, and present Neogap’s approach to personalised cancer immunotherapy. We are proud to be among the selected Nordic companies joining the programme and excited to connect with the broader life science community in New York.
EDIT: Andrea won the Grand Pitch Finale!!!
More information at SACCNY Innovate Nordics.

CIMT Annual Meeting 2025
Date: 12-14 May
Location: Mainz, Germany
We are pleased to announce our participation in the 22nd CIMT Annual Meeting. Hans Grönlund, founder and CSO of Neogap Therapeutics, will present a poster highlighting our groundbreaking technologies. Take this opportunity to engage with Hans and delve into our pioneering therapeutic approaches.
More information at CIMT Annual Meeting.

SACCNY Innovate Nordics 2025 – Kick-off
Date: 8 May
Location: Stockholm, Sweden
We are proud to take part in The Nordic Pitch in Stockholm, hosted by the Swedish-American Chamber of Commerce – New York (SACCNY) and EY as part of the Innovate Nordics Acceleration Program. Our COO, Andrea Salmén, will pitch Neogap and share our vision for the future of personalised immunotherapy – using precision-selected neoantigens to develop next-generation T-cell therapies. The event brings together leading voices in health innovation and Nordic capital markets. We look forward to sharing our progress and connecting with others who share our ambition to transform cancer treatment.
More information at SACCNY Innovate Nordics.

Nordic Precision Medicine Forum 2025
Date: 28-29 April
Location: Stockholm, Sweden
Meet Hans Grönlund, founder and CSO of Neogap Therapeutics, for a personal discussion on our cutting-edge therapeutic technologies at the Nordic Precision Medicine Forum 2025.
More information at Nordic Precision Medicine Forum.

KI Innovations InvestorDay 2025
Date: 10 April
Location: Solna, Sweden
We invite you to KI Innovations InvestorDay 2025 to engage with Hans Grönlund, founder and CSO of Neogap Therapeutics, and explore our innovative therapeutic approach and potential opportunities.
More information at KI Innovations InvestorDay.

Swiss Nordic Bio 2025
Date: 13 March
Location: Zurich, Switzerland
We are thrilled to announce our participation in Swiss Nordic Bio, a premier event connecting biotech, pharmaceutical, and healthtech companies with top investors and industry leaders. This exclusive opportunity allows us to showcase our innovative therapy, engage in face-to-face meetings with potential investors and partners. We look forward to forging valuable connections and exploring new avenues for collaboration in the dynamic healthcare landscape.
More information at Swiss Nordic Bio.

Biologics World Nordics 2025
Date: 5-6 March
Location: Stockholm, Sweden
Guro Gafvelin, the CTO at Neogap Therapeutics, will deliver a presentation on personalised T-cell therapies for cancer at Biologics World Nordics 2025. Her talk will highlight our innovative cell therapy approach, showcasing our commitment to advancing cancer treatment. We invite you to engage with Guro, as well as her colleagues Andrea Salmén, COO, and Kristine Bylund, Head of Cell Therapy Production and Development, during the event to discuss our cutting-edge cancer therapy and explore potential investment opportunities and partnership possibilities.
More information at Biologics World Nordics 2025.

ATMP Sweden 2024
Date: 25-26 November
Location: Malmö, Sweden
Neogap will participate in the annual ATMP Sweden conference in Malmö, where we will engage with peers to discuss advancements in therapeutics. We are excited to present our latest developments in the poster titled “A first in human Phase I/IIa trial of personalised Tumour-Trained Lymphocytes, pTTL, derived from regional lymph nodes for treatment of colorectal cancer”.
More information at ATMP Sweden.

SITC 2024
Date: 6-10 November
Location: Houston, U.S.
We will be at the Society for Immunotherapy of Cancer (SITC) Conference to showcase our poster “Personalized Tumor-Trained Lymphocytes – A neoantigen targeted T cell therapy product for treatment of colorectal cancer”.
Guro Gafvelin, our CTO, and Sofia Berglund, Principal Scientist Clinical Development, will be there to connect and discuss deeper insights.
More information at SITC 2024.

BIO-Europe 2024
Date: 4-6 November
Location: Stockholm, Sweden
Andrea Salmén, COO, and Ola Nilsson, Head of Neoantigen Production & Development, will be there to discuss advances in immuno-oncology and explore partnerships for our innovative cell therapy program.
More information at BIO-Europe.